AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7628886 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit of seven exercises
Number of subjects: 20
Study 2649120 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg twice daily increased to 10 mg twice daily after two weeks)
Number of subjects: 25
Study 2649120 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 25
Study 10943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 30
Study 10943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 30
Study 10943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31140002 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic drainage
Number of subjects: 60
Study 31140002 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic drainage
Number of subjects: 60
Study 30907301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel and aspirin)
Number of subjects: 760
Study 30907301 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase (0.9 mg/kg)
Number of subjects: 760
Study 26815593 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 78
Study 26815593 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 78
Study 26078877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (I) - Growing Leaps and Bounds program delivered by health care providers at 7-9 well-baby visits over 2 years.
Number of subjects: 232
Study 26078877 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - No specific intervention mentioned.
Number of subjects: 232
Study 23524340 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral weight loss (4 months)
Number of subjects: 140
Study 23524340 — intervention group
Group type: COMPARATOR
Intervention: Migraine education (control)
Number of subjects: 140
Study 23524340 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 140
Study 21474517 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist referral based on a probability of pre-eclampsia of at least 15% or an abnormal uterine artery Doppler waveform
Number of subjects: 3572
Study 21474517 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3572
Study 19296748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 123
Study 19296748 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 16703777 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil cream with tape occlusion
Number of subjects: 40
Study 16703777 — intervention group
Group type: COMPARATOR
Intervention: Tape occlusion alone
Number of subjects: 40
Study 15015668 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine wafers
Number of subjects: 24
Study 15015668 — intervention group
Group type: COMPARATOR
Intervention: Placebo wafers
Number of subjects: 24
Study 11845814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily for 12 months
Number of subjects: 85
Study 11845814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 9598884 — intervention group
Group type: EXPERIMENTAL
Intervention: Futuro wrist orthosis
Number of subjects: 40
Study 7618651 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0
Study 7618651 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 2923081 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokeless tobacco (ST) use
Number of subjects: 58
Study 2923081 — intervention group
Group type: COMPARATOR
Intervention: Nonusers (control group)
Number of subjects: 58
Study 2923081 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic ST use
Number of subjects: 58
Study 320061 — intervention group
Group type: EXPERIMENTAL
Intervention: Diftalone (1,000 mg during the 1st week; 750 mg the 2nd week; 500 mg from the 3rd week on)
Number of subjects: 30
Study 320061 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone (400 mg during the 1st week; 300 mg the 2nd week; 200 mg from the 3rd week on)
Number of subjects: 30
Study 31439579 — intervention group
Group type: EXPERIMENTAL
Intervention: Taselisib combined with tamoxifen (20mg once daily)
Number of subjects: 30
Study 31439579 — intervention group
Group type: EXPERIMENTAL
Intervention: Taselisib (2 or 4 mg in an intermittent or continuous schedule)
Number of subjects: 30
Study 31439579 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor (ct)DNA studies
Number of subjects: 30
Study 28927491 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronate plus CPAP
Number of subjects: 102
Study 28927491 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution plus CPAP
Number of subjects: 102
Study 28927491 — intervention group
Group type: COMPARATOR
Intervention: CPAP-only
Number of subjects: 102
Study 26410207 — intervention group
Group type: EXPERIMENTAL
Intervention: ERIGO training (30 sessions)
Number of subjects: 20
Study 26410207 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapist-assisted verticalization training (30 sessions)
Number of subjects: 20
Study 24093352 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited health literacy
Number of subjects: 226
Study 21358807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion-exchange water softener plus usual eczema care
Number of subjects: 336
Study 21358807 — intervention group
Group type: COMPARATOR
Intervention: Usual eczema care alone
Number of subjects: 336
Study 19060764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 0
Study 19060764 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin
Number of subjects: 0
Study 17882839 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant proinflammatory cytokines
Number of subjects: 0
Study 17882839 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ligands for Toll‐like receptors
Number of subjects: 0
Study 17882839 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycomponent vaccine containing antigens of opportunistic bacteria (Immunovac VP‐4)
Number of subjects: 0
Study 15220700 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (n = 86)
Number of subjects: 118
Study 15220700 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (n = 32)
Number of subjects: 118
Study 15220700 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of d4T
Number of subjects: 118
Study 15220700 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment using abacavir or zidovudine
Number of subjects: 118
Study 15220700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlactatemia symptoms
Number of subjects: 118
Study 15220700 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum transaminases normalization after d4T discontinuation
Number of subjects: 118
Study 11348605 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 to 40 mg/day
Number of subjects: 6605
Study 11348605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6605
Study 9517940 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD (4 mg/kg of body weight daily) for up to 6 weeks
Number of subjects: 133
Study 7822089 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids (40 mg of prednisone equivalent)
Number of subjects: 28
Study 7822089 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids (40 mg of prednisone equivalent) + Cyclophosphamide (100 mg)
Number of subjects: 28
Study 7822089 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids (40 mg of prednisone equivalent) + Cyclosporine (5 mg/kg)
Number of subjects: 28
Study 7822089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatments (Cyclophosphamide or Cyclosporine)
Number of subjects: 28
Study 31153362 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 week physiotherapy programme (6-8 sessions) of manual therapy, exercise and upper limb neural unloading tape
Number of subjects: 64
Study 31153362 — intervention group
Group type: COMPARATOR
Intervention: Weekly phone advice (control)
Number of subjects: 64
Study 28304350 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional bread (low in starch, rich in fibers, 7 g/100 g, beta glucan/starch ratio of 7.6:100 g/g)
Number of subjects: 0
Study 28304350 — intervention group
Group type: COMPARATOR
Intervention: Regular white bread (control group)
Number of subjects: 0
Study 28304350 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional bread
Number of subjects: 0
Study 25572800 — intervention group
Group type: EXPERIMENTAL
Intervention: ISTOP‐ADE system (interactive voice response system paired with pharmacist support)
Number of subjects: 2200
Study 25572800 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 2200
Study 23889689 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported measures
Number of subjects: 301
Study 23889689 — intervention group
Group type: COMPARATOR
Intervention: Professional teeth cleaning
Number of subjects: 301
Study 22255101 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with ramp platform perturbations at vestibular velocities (1, 2, 4 deg/sec; VESTIB n=6)
Number of subjects: 12
Study 22255101 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical balance training (CBT n=3)
Number of subjects: 12
Study 22255101 — intervention group
Group type: COMPARATOR
Intervention: Training with ramp platform perturbations at non-vestibular velocities (0.5, 8, 16 deg/sec; Non-VESTIB n=3)
Number of subjects: 12
Study 22255101 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n=4)
Number of subjects: 12
Study 19389331 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 77
Study 19389331 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation antipsychotics (FGAs)
Number of subjects: 77
Study 19389331 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder trials
Number of subjects: 77
Study 16797329 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly, calcium 1 g daily, calcitriol 0.5 mug daily
Number of subjects: 59
Study 16797329 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 59
Study 16797329 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (n=31)
Number of subjects: 59
Study 14676153 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdissection needle cautery at 8 W
Number of subjects: 42
Study 14676153 — intervention group
Group type: COMPARATOR
Intervention: Standard monopolar electrocautery at 20 W
Number of subjects: 42
Study 10845174 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuartnatal Plus
Number of subjects: 30
Study 10845174 — intervention group
Group type: EXPERIMENTAL
Intervention: Materna
Number of subjects: 30
Study 10845174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12799797 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound at 0.3 W/cm2
Number of subjects: 30
Study 12799797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound at 0.7 W/cm2
Number of subjects: 30
Study 12799797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound at 1.0 W/cm2
Number of subjects: 30
Study 8407397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron radiotherapy
Number of subjects: 25
Study 8407397 — intervention group
Group type: COMPARATOR
Intervention: Conventional photon and/or electron radiotherapy
Number of subjects: 25
Study 3006516 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.01-10 microM)
Number of subjects: 20
Study 3006516 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.01-10 microM)
Number of subjects: 20
Study 3006516 — intervention group
Group type: COMPARATOR
Intervention: Supplemental calcium
Number of subjects: 20
Study 29023666 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA), choline, and uridine‐5‐monophosphate (UMP) supplementation for 2 years
Number of subjects: 40
Study 29023666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 40
Study 26971109 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load exercises with partial vascular occlusion (PVO) at 30% of 1-RM for 6 weeks
Number of subjects: 34
Study 26971109 — intervention group
Group type: COMPARATOR
Intervention: High-load exercises without PVO at 70% of 1-RM for 6 weeks
Number of subjects: 34
Study 24481031 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 130
Study 24481031 — intervention group
Group type: COMPARATOR
Intervention: cTBNA
Number of subjects: 130
Study 24481031 — intervention group
Group type: EXPERIMENTAL
Intervention: EBB
Number of subjects: 130
Study 24481031 — intervention group
Group type: EXPERIMENTAL
Intervention: TBLB
Number of subjects: 130
Study 24481031 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA + TBLB
Number of subjects: 130
Study 24481031 — intervention group
Group type: COMPARATOR
Intervention: cTBNA + EBB + TBLB
Number of subjects: 130
Study 22326505 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry odor with strawberry and tomato images (Experiment 1)
Number of subjects: 63
Study 22326505 — intervention group
Group type: EXPERIMENTAL
Intervention: No odors with strawberry and tomato images (Experiment 2)
Number of subjects: 63
Study 22326505 — intervention group
Group type: COMPARATOR
Intervention: Strawberry odor with strawberry and tomato images (Experiment 2)
Number of subjects: 63
Study 19897063 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (group 1, n=20) continued for 96 weeks
Number of subjects: 54
Study 19897063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 2, n=20) after 96 weeks of raloxifene
Number of subjects: 54
Study 19897063 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 3, n=14)
Number of subjects: 54
Study 18414411 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/gemcitabine
Number of subjects: 53
Study 15598193 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's program
Number of subjects: 122
Study 15598193 — intervention group
Group type: COMPARATOR
Intervention: Mixed-gender community programs
Number of subjects: 122
Study 15598193 — intervention group
Group type: COMPARATOR
Intervention: Mixed-gender hospital program
Number of subjects: 122
Study 11846350 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction intervention using a developmentally appropriate electronic toy
Number of subjects: 29
Study 11846350 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 29
Study 10022643 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy
Number of subjects: 64
Study 10022643 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy
Number of subjects: 64
Study 10022643 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal S-shaped pouch after total gastrectomy
Number of subjects: 64
Study 7790794 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation therapy
Number of subjects: 150
Study 7790794 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline therapy
Number of subjects: 150
Study 1691355 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 20
Study 1691355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 371048 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanamycin (1 gm four times a day) and erythromycin (750 mg three times a day)
Number of subjects: 77
Study 371048 — intervention group
Group type: COMPARATOR
Intervention: Kanamycin with placebo
Number of subjects: 77
Study 31772611 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (15 g for 21 days)
Number of subjects: 38
Study 31772611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 15 g for 21 days)
Number of subjects: 38
Study 28592166 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bilateral thoracic paravertebral infusion of 0.5% lidocaine (1 mg.kg‐1.hr‐1)
Number of subjects: 50
Study 28592166 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous infusion of lidocaine at the same rate through catheters inserted at the same locations
Number of subjects: 50
Study 28592166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 25361165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fab/Fab
Number of subjects: 121
Study 25361165 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')2/F(ab')2
Number of subjects: 121
Study 25361165 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')2/placebo
Number of subjects: 121
Study 24958605 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐then‐AT (8 weeks resistance training followed by 8 weeks aerobic exercise training)
Number of subjects: 75
Study 24958605 — intervention group
Group type: COMPARATOR
Intervention: CE‐then‐AT + RT (8 weeks of 'sham' training followed by 8 weeks concurrent aerobic and resistance training)
Number of subjects: 75
Study 24958605 — intervention group
Group type: COMPARATOR
Intervention: CE‐then‐AT (8 weeks 'sham' training followed by 8 weeks aerobic training)
Number of subjects: 75
Study 21527575 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) doses of 30 mg, 50 mg, and 70 mg
Number of subjects: 0
Study 21527575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19258602 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate and calcium‐phosphate cements
Number of subjects: 22
Study 19258602 — intervention group
Group type: COMPARATOR
Intervention: Calcium‐phosphate cement
Number of subjects: 22
Study 17718702 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 14
Study 17718702 — intervention group
Group type: COMPARATOR
Intervention: Control (no gabapentin)
Number of subjects: 14
Study 15084807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE) 20 mg/kg/day (max. 500 mg) b.i.d. for 5 days
Number of subjects: 1952
Study 15084807 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (PenV) 50,000 IU/kg (30 mg/kg) t.i.d. for 10 days
Number of subjects: 1952
Study 11240535 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 256
Study 11240535 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 256
Study 9278836 — intervention group
Group type: COMPARATOR
Intervention: Low-flow anesthesia only (control, n = 10)
Number of subjects: 30
Study 9278836 — intervention group
Group type: COMPARATOR
Intervention: Low-flow anesthesia with additional reflective blankets (blanket, n = 10)
Number of subjects: 30
Study 9278836 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow anesthesia with active forced-air warming (forced-air, n = 10)
Number of subjects: 30
Study 8315425 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and Dacarbazine (AD)
Number of subjects: 340
Study 8315425 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, Dacarbazine, and Ifosfamide (ADI)
Number of subjects: 340
Study 3625594 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hyperventilation (Group FB: fast and deep breathing)
Number of subjects: 48
Study 3625594 — intervention group
Group type: COMPARATOR
Intervention: Slow breathing (Group SB)
Number of subjects: 48
Study 3625594 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing (Group NB)
Number of subjects: 48
Study 30031747 — intervention group
Group type: EXPERIMENTAL
Intervention: Online-delivered walking intervention with access to the REACH website and personalized step goals.
Number of subjects: 171
Study 30031747 — intervention group
Group type: COMPARATOR
Intervention: Comparison group received a paper diary and generic step goals.
Number of subjects: 171
Study 30031747 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received a pedometer.
Number of subjects: 171
Study 29800179 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency follow-up testing (computed tomography and carcinoembryonic antigen at 6, 12, 18, 24, and 36 months after surgery)
Number of subjects: 2509
Study 29800179 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency follow-up testing (computed tomography and carcinoembryonic antigen at 12 and 36 months after surgery)
Number of subjects: 2509
Study 26068576 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Cisplatin with concomitant gefitinib (arm A)
Number of subjects: 105
Study 26068576 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Cisplatin with sequential gefitinib (arm B)
Number of subjects: 105
Study 26068576 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus Cisplatin alone (arm C)
Number of subjects: 105
Study 24938526 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART with Tenofovir/Emtricitabine plus Nevirapine
Number of subjects: 625
Study 24938526 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART with Tenofovir/Emtricitabine plus Lopinavir/Ritonavir
Number of subjects: 625
Study 24938526 — intervention group
Group type: COMPARATOR
Intervention: Non-SCR group
Number of subjects: 625
Study 24938526 — intervention group
Group type: EXPERIMENTAL
Intervention: SCR group
Number of subjects: 625
Study 22190027 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced dehydration with no diuretic (DN)
Number of subjects: 25
Study 22190027 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced dehydration plus diuretic (DD; furosemide, 40 mg)
Number of subjects: 25
Study 22190027 — intervention group
Group type: COMPARATOR
Intervention: Euhydration (EU)
Number of subjects: 25
Study 20704666 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal injection of steroid
Number of subjects: 0
Study 20704666 — intervention group
Group type: COMPARATOR
Intervention: Transforaminal injection of local anesthetic
Number of subjects: 0
Study 20704666 — intervention group
Group type: COMPARATOR
Intervention: Transforaminal injection of saline
Number of subjects: 0
Study 20704666 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of steroid
Number of subjects: 0
Study 20704666 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of saline
Number of subjects: 0
Study 17430436 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually adjustable saddle-type chairs with wheels and desks with comfort curve and arm support
Number of subjects: 97